#SenecaProud

Pat Perdue  00:00

Hi, I'm Pat Perdue, and I'd like to welcome you to Season Three of the Seneca Proud podcast. This is a co-production between my company Ycastr and Seneca College in Toronto. These days because of the global pandemic, yep, that's still a thing. So, much of Seneca is remote from working to teaching to studying. But hey, Seneca College has always been more than a place or a bunch of buildings. Seneca College is an idea. It's a vision for a better future. And it's a challenge to do what it takes to transform that vision into reality. And that is exactly what Season Three is all about Seneca College is transforming, there are really exciting changes in the works. And this season, we get to take a close look at some of those changes, as well as the people who are helping make those changes happen. So, if you haven't already, subscribe, and download and join me as we discover the changes and meet the people who are transforming vision into reality. Because the next episode of Seneca Proud starts now.

Welcome back to the Seneca Proud podcast. I'm Pat Perdue, and I'm so glad you're here to join us today. You might have heard there's this thing called COVID. And it’s sort of completely changed how the world does, I don't know, just about everything. Something that we often comment on has been the speed of innovation, from quickly moving classes to an online environment to students fully attending all their classes online, even to things like how we shop, everything is different. We've all been challenged to innovate, and business has innovated as well. While we often think of how restaurants and retailers and yoga studios and spas and so many others have had to change the way they do business, innovation has also come in the form of industry providing solutions to new or suddenly urgent problems. Like let's say you can't store a vaccine in a climate-controlled location. How do you keep it at the appropriate temperature for as long as possible? A couple of years ago, that question might not have had the urgency it does today. With the emergence of COVID-19 and the current distribution of vaccines. solving this problem can save lives right away, bringing more vaccines to more people, suddenly this solution has become urgent. 

It just so happens that Seneca College along with Seneca Innovation, and industry partners are involved in some leading edge applied research that have amazing practical outcomes that helps save lives, like the project I just described. And in today's show, we'll look at a couple of those innovations as well as dive into the crucial role Seneca Innovation plays in helping ideas transform into products in the marketplace. 

Our guests today are Dr. Frank Mirante, Professor and Applied Research Co-ordinator at Seneca’s School of Biological Sciences and Applied Chemistry. We're also joined by Chad Lever, the Director of Applied Research in Seneca Innovation. Let me give you some background, and then we'll launch right into the conversation. In addition to being Professor and Applied Research Co-ordinator at Seneca’s School of Biological Sciences and Applied Chemistry, Dr. Meranti is also the Principal Scientist for the Seneca Center for Innovation in Life Sciences. Dr. Meranti has been instrumental in establishing applied research capabilities at Seneca. He holds a PhD from the University of Toronto, and has covered multiple disciplines including biochemistry, molecular biology, and human genetics. Dr. Meranti was the recipient of Seneca Innovation’s Research Leader of the Year award in 2020. Dr. Meranti was also nominated for his efforts in two applied research projects conducted at Seneca College to combat COVID 19. The first project was with Canoda Health, and it helped produce three key proteins associated with COVID-19 for use in an immunodiagnostic device. The second project with Giftgowns, is working to produce a long-lasting antimicrobial spray to sanitize surfaces. 

We are also joined by Chad Lever. In addition to his role as Director of Applied Research at Seneca Innovation. Chad has led community, provincial and national research programs focused on the assessment of health system transformation, technology innovation, data asset creation and advanced analytics. Most recently, he led innovation and research partnerships focused on improving health systems sustainability and modernization through digital health solutions and virtually enabled models of care. Chad has a Masters of Science in community health and epidemiology, and an MBA from both Cornell and Queens Universities. Our conversation touches on some of the leading-edge projects that Frank and his team are currently working on in partnership with Seneca Innovation. But we start our conversation with Chad Lever sharing with us what Seneca Innovation is and why it's such an important and exciting part of Seneca College. I'm so excited to share this conversation with you. Here's Chad.

 

Chad Lever  05:25

Seneca Innovation supports applied research, innovation and entrepreneurship activities at Seneca. We do so through three tiers of our department, which is applied research, HELIX entrepreneurship, or HELIX Ventures, and Seneca Innovates, which is a program internal to Seneca, really capitalizing on the great ideas of you know, cytokines and how to make Seneca better. I think we're focusing our talk today, largely on applied research. But of course, I invite your listeners to visit Seneca Innovations’ website. So, when it comes to applied research, our role is to collaborate with industry in and around the GTA, Ontario and even across Canada to address their business and technical challenges, through access to unique expertise that exists at Seneca across all of our faculties, the infrastructure within Seneca as it relates to specific labs that we have and other assets. As well, as the funding opportunities that are available to Seneca via federal, provincial and other granting agencies. Maybe as a bit of a background, just in the last year, Seneca had 57 applied research projects. We currently have 35 active research projects already this year. Last year, there were 46 faculty investigators supporting projects, and all of our projects, hire and engage students, research assistants, who are usually in their upper years at Seneca in their various programs. And last year, we had 190 Seneca students support our research projects. And these research projects supporting businesses are integral to them advancing their innovation research and development strategies. And many of them see applied research as a way to onboard potential staff and 13 jobs were offered to our research assistants last year. And overall last year, Seneca innovation secured $2.8 million in research funding from our various funding sources.

 

Pat Perdue  07:24

That was huge, what you just described, I can't even get my mind around what all that encompasses. So perhaps walk us through a day in the life of Innovation Seneca, what happens, what kind of conversations take place? Sounds really exciting.

 

Chad Lever   07:44

Yeah. As you may know, there are a number of research specializations, across Seneca, whether it be in the life sciences, software development, data and data science, as well as arts and animation, it really runs the whole gamut. And what ends up happening is, an innovator, a start-up, who is established has come to Seneca and needs support, whether it be from engineering or life sciences, to advance a specific innovation. And, our role is to refine for them what expertise, they specifically need, how that aligns to specific faculty and expertise and the infrastructure that we have at Seneca and then work on the funding opportunity with the federal or provincial agency to support that. Which essentially supports the cost of the research to support and mentor the research assistants who are Seneca students. And, you know, hire those students and execute those projects, which can run in some instances from, three to six months, and in others where we're doing really big social innovation projects, they can last up to three years, and they can span a variety of disciplines.

 

Pat Perdue  08:56

Amazing. Speaking of really big projects, Frank, I'm sort of glancing over to you right now. Can you share with us a little bit of the work that you're doing, and the research projects that you're involved with, with Innovation, Seneca?

 

Frank Mirante  09:11

At the current time where I'm actually involved, either solely or fortunately, and I would almost say in a privileged manner, with other very talented faculty members, as well as some of the upper semester or graduate or graduated students some of the projects, three out of the four are actually COVID directed. And some of the companies include VivaVax  Corporation, where we're looking to, again, this is a collaborative project with another very talented faculty member, where we're looking to actually coat the exterior of vials with a particular emphasis on vaccine vials. So that way, it protects the content from from heat transmission. You can imagine in the current workflow for typical vaccination, and vaccines are getting a lot of press coverage. Currently, somebody needs to go to a refrigerator or cold storage facility retrieve the vial, and there's going to be multiple doses of vaccine being administered. Typically, if you look at the Pfizer vaccine, upwards of six, and so some of those components within the vial can be very heat labile. So, the coating that we're aiming to optimize and augment will actually buffer temperature fluctuations from within the vial so it preserves the content of that material. And the company VivaVax  actually has a forward reaching vision because it's not only vaccines, we see a dramatic increase in the utilization of biologics and monoclonal antibodies. And these are all components that may have a heat sensitivity component. And that exterior coating or insulation is actually the aerogel type of a composite, a nanostructured aerogel it enables that vaccine to sit at room temperature for a much longer period of time without losing efficacy.

 

Pat Perdue  11:18

Amazing and share with us how you became connected with VivaVax , did they approach you? Or did you have this great idea and think I need somebody from the industry to participate? How did how did all that happen?

 

Frank Mirante  11:33

So actually, one of the other professors who is instrumental in engineering the nanocomposite, was approached with just the vague possibility of maybe doing something with the company. But as you can imagine, I think this is where the strength of collaboration comes in. We have a very talented polymer nanostructured chemist, but then we had to marry that or pair that with the ability to assess the functionality. And we can do a variety of physical methods, essentially put a thermocouple into the vial. But it was really also important to demonstrate that in a real sense, and of course, we didn't want to rely on infectious or potentially infectious COVID viral material. S,o my role in the project was to develop suitable mimetic systems or surrogate models that can fully demonstrate the utility of the coating for both a proteinaceous like a protein type vaccine with some of these split subunit vaccines, or an attenuated virus vaccine, but not have to deal with not only expensive but also potentially infectious material.

 

Pat Perdue  12:52

Nice. And you reference some other folks that are involved in the project. Are there any shoutouts that you'd like to provide? 

 

Frank Mirante   12:59

Yeah, so all my heart goes out to Barkhad, who was one of my most esteemed colleagues, and professors, and also a collaborator from another project, which is Brian Chalk for collaborating wholeheartedly with the Conotta health project as well.

 

Pat Perdue  13:17

Amazing, amazing. Yeah, shout outs to both of them. And I'm so interested in the genesis of this project, because it sounds like it was a notional project at first, like, maybe we can work together and find some synergy. And it feels like it gelled into this specific project, is that an accurate description of how that worked?

 

Frank Mirante  13:39

That's a beautiful way to describe it. And it really is the synergy between the company. We were fortunate to work with a very talented, professional company, which is Alice Chang, who was the one that originally wanted to do something with Seneca Innovation. Also having the collection of the individuals in the room or at least, on WebEx calls to scope out some ideas, investigate the potentials, and then eventually actually put that into a work plan that we can execute.

 

Pat Perdue  14:16

How very interesting and, you know, even the iteration journey continues, because at a certain point, Chad and your department was brought in, to continue to move this forward, and I guess add some definition to the project. Chad at what point were you brought in to begin to have this conversation or was it from day one?

 

Chad Lever   14:40

We've been working with VivaVax , prior to my joining Seneca innovation, which was just back in July, in the midst of the pandemic, and in the evolution of that work really, is accentuated by the Seneca Center for Innovation Life Sciences, which launched this November and the VivaVax . Work will continue under that portfolio which is a five year grant of $2 million awarded to Seneca Innovation, and is to stand up our work in diagnostics as well as Cosmetic Science. And as you may know, Cosmetic Sciences at Seneca is the only program of its kind in Canada. My role is, just as you were saying, the shout outs to the team with so many projects, it does take a village. Our research managers, Ralph flatac, Andrew Payton and Tina Perricone, work tirelessly, with faculty like Frank, to support the research teams and to advance once the project's, come to the end and have, completed deliverables for the partner there's always more research questions, as is the case, always with research. And those companies have different channels of innovation, that their development strategies, persist, and we're there to help them, on that journey.

 

Pat Perdue  16:03

Amazing, amazing. And when a research project comes to your department, are you competing for a limited resource of funds so the onus now becomes on you to make this happen, and it's not necessarily a slam dunk? You're on the hook to win the funds, so to speak? Is that a correct description?

 

Chad Lever   16:24

Yes, absolutely. The majority of cases it is as such, in that, we have to make a case to the granting agency. What is the real impact of the project? How will it be integrated into the company? How does that position the company for growth within the Canadian context, and what future research opportunities may persist? After that, and in as much as you know, the majority of our projects, we are securing funding from provincial or federal sources, we are also open for a fee for service projects as well. So, companies in the applied research context, are approaching us not whereby the innovation is in the critical path of the company growth, they have various areas they want to develop. They want to explore new areas of innovative, they want to test AI or machine learning or natural language processing with our data science group on data assets that they have. Maybe we do so in partnership with Sosa, which is one of our advanced data partners in the city here. And, when we do that, we are also saying, okay, do we need funding for this? And yes, federal and provincial sources do have a substantive application process that we have to go through.

 

Pat Perdue  17:38

Amazing, amazing.  And, Frank, I'm curious to continue about the VivaVax  conversation. Was that just luck that the project happened to be so timely to what's happening today with regards to COVID? Or was it specifically conceived of to say, hey, we could really have an impact on COVID vaccine distribution so we should probably work on that?

 

Frank Mirante 18:04

I actually have a few of our projects for I would say the timing was very serendipitous because VivaVax actually had their prototype aerogel coating, prior to, or at least in development while COVID was developing. But then we see how suddenly this product can fulfill that need. And that was actually seeing some companies were able to effectively pivot their platforms slightly so that we can accommodate the COVID crisis. And that I think is best exemplified by our collaboration with Giftgowns as well, original emphasis and the bulk of the work that we had initiated was actually to create an anti-microbial, but with the growing need for anti-viral sanitation of surfaces, particularly, we were able to justify creating a model system to address viruses, in particular, without excluding actually the original scope of the work. But we were able to broaden the horizon to accommodate COVID.

 

Pat Perdue  19:19

So Frank, in your world, it sounds like there has been a massive, I guess, acceleration in the pace at which you are developing these products, because all of a sudden you find yourself with a huge and urgent market need.

 

Frank Mirante  19:35

Yes. And I think we were very fortunate to work collaboratively with the company as well as some of our talented project managers to redirect some of the emphasis on some of the research so that way, we could have a more directed COVID focus. And I think that was best exemplified by our collaboration with Giftgowns. Originally, were looking to have a long-acting antibacterial nanocomposite. But we very quickly redirected that to be effective against COVID and respiratory viruses in general. And I think we're very fortunate that we do have that ability and that fluidity within our working relationship with both the company as well as our Center for Innovation.

 

Pat Perdue  20:31

Speaking of the Center for Innovation, Chad, from your end, has this sudden impetus to get to market quickly impacted your role in securing funding or preparing documentation or all of the other crucial things that your department does?

 

Chad Lever  20:49

Short answer is yes. And I think it's important to note that our primary funder is, the Natural Sciences and Engineering Research Council of Canada. Our answer was extremely responsive as the pandemic was emerging in Canada when COVID came to town and had established applied research rapid response grants back in the spring, to which we have the Canotta project and the Trinetra project. Frank's been talking about the Canotta project. The Trinetra project is more of a data science and machine learning AI project, using Blockchain to establish confirmed, trusted credentials for personal support workers to support certifications, training and geography of those workers; to better schedule and position those workers into the workforce. So, a key aspect of, as many people know, PSWs are on the front line. And this work is about supporting the resourcing of those professionals in the industry. The funding agencies were responsive and their call with these funds allowed our team to really mobilize, to identify current and potential partners that had concepts that align to this funding. We moved on those applications extremely quickly.

 

Pat Perdue  22:11

Amazing. So, were you describing sort of an active outreach or call for applications that was specifically targeted toward this new funding that became available?

 

Chad Lever  22:23

Yup, our team would fully mobilize to find the partners that had the innovations. And, the industry itself is moving at breakneck speed in terms of innovation and, can our, operations, be in step? It's a bit difficult with the burden of applying and preparing these applications and securing faculty at the college, and as you know, faculty are teaching. We are trying to keep up as much as possible. But yeah, innovators are innovating. And I think we will be seeing that as these stories come to bear.

 

Pat Perdue  23:02

And you all are the cutters of red tape. It sounds like

 

Chad Lever  23:06

Ninjas!

 

Pat Perdue  23:10

Awesome, awesome. So, Frank, for the projects that you're on. They're super exciting. They're super timely, and there's an urgent need for these to go to market. Is there a sense right now or is it too early? Or are you at liberty to suggest when go to market date might happen for the projects that you're in on?

 

Frank Mirante  23:31

I can speak maybe to the Giftgowns project in the sense that any product that needs depth requires or is intended to have a sanitisation type claim actually becomes a product that is scrutinized and approved by Health Canada. We have sufficiently evolved the product to actually be assessed now for Health Canada submission.

 

Pat Perdue  24:02

That is super exciting.

 

Frank Mirante  24:05

That is really exciting, because it means that we can have a natural product that confers long lasting surface sanitization hopefully on the market within certainly the year.

 

Pat Perdue  24:18

Amazing. Amazing. And getting back to the iterative aspect of this whole process. You know, we don't have the benefit of, oh, by the way conversations or hey, what's going on conversations or those magical, I call them coffee shop conversations, that lead to these great light bulb moments that really can't be planned but it's where all the best ideas come from. Do you find that both of your worlds are a little bit negatively impacted by COVID simply because we don't have that opportunity anymore to have these random conversations?

 

Frank Mirante  25:00

Well, I certainly fully agree with you. Because I think sometimes you can change the world over a cup of coffee. I really, truly believe that. And I think I know, at least in my research and academic career, I can probably cite some very significant examples of that. And I would say it is impacting that you can't just have these spontaneous over coffee type conversations. But with a bit of effort, I think people have gone to great lengths to be able to reach to connect through digital platforms like ours, what we're doing today. And it's been working. I think there's still a need for that face-to-face interaction, or spontaneous type of interaction, but I think we're doing okay.

 

Pat Perdue  25:53

Well, clearly, you're doing a lot more than okay, because you've got a couple of really super important projects that are absolutely bound to make a massive, massive difference. And Chad, I'm glancing at you now, how has the lack of those, oh, by the way, conversations impacted your ability to nurture some of these projects into a state where they're really something that you and your team can get behind and secure funding for?

 

Chad Lever  26:18

To answer that question, I think we are, adept at the nurturing part. We are, bringing the projects to the fore, to the faculty launching them. And they are mobilizing. We have applications for students, we're hiring. Students are on campus because applied research is an essential service, they're in the labs, and they're working. But the face-to-face piece is, you know, we're in the biggest city in the country. We have multiple innovation hubs, like Venture Lab, like Mars with lots of innovation happening. And much of the work at, engaging the community is, face to face. Being at those lunches, being at those breakfasts. So, then what's coming out of U of T; what's coming out of York, you know, in terms of new major scientific innovations in their incubators you know, can start to work with us. Because the real benefit of doing applied research, in the polytechnics and ideally, at Seneca is that our intellectual property requirements, give the intellectual property to the partner, the partner owns the intellectual property. And I'm glad you mentioned that to Frank and said, oh, you know, are we at liberty to disclose? We have a lot of patents coming out of our work. We encourage our faculty to, of course, publish the results. And they are allowed to publish the results. But of course, we do so in step with our partners’ requirements. We don't publish when they're in the patent phase. And we work with the partners on what to publish. I think, yeah, that face to face piece, especially since I started in the middle of the pandemic, is a, I'm really looking forward to getting back to that to get the buzz going about working with Seneca.

 

Pat Perdue  27:59

I'm sure but it sounds like you're certainly managing very well, in spite of those circumstances. And Chad, you mentioned, students. I'm curious about how students can get involved in this research and benefit not only from the work but perhaps benefit from some of the industry contacts that they may make as a result of being part of the research, how can they get involved, if it's something that they want to do?

 

Chad Lever  28:25

Well, first, they can look at Seneca Works, obviously, which is where we post the research assistant positions; they can talk to their professors, and see if they're involved in applied research and what and if they are, how they can get involved. They themselves might be innovators, and have connections in the community, maybe their family members work in a company trying to innovate in this space. Think about Seneca because our faculty can solve a number of business challenges facing the sector today. Students can get involved in multiple ways, contact or visit our website, speak to your professor, look on Senate Works and, you know, bring ideas to us. We are open for the conversation.

 

Pat Perdue  29:09

And that last point, how mature does an idea need to be before it's ready to be presented to you?

 

Chad Lever  29:18

It's not so much how mature the idea needs to be because it can just be a glimmer in someone's eye. But in order for the company to be eligible for the funding channels that we have, they have to be incorporated for at least two years, have two or more full time employees and have ideally a non-residential corporate address. So, there's some eligibility requirements to secure the funding. Hey, if you're less than that, and you don't have good investor seed funding, we're open, like I said, for fee for service, but those are baseline eligibility requirements that we look for.

 

Pat Perdue  29:52

Makes sense. Thank you. And, Frank, from your perspective, if there's somebody maybe from the industry or from the academic community that would like to participate in this, what advice might you be able to give, you know, to, to make that process as easy as possible?

 

Frank Mirante  30:10

I really believe it just initiates with an email, either an email or a phone call. And I think we have a lot of very talented people that and then again, nice shout out goes to both Tina Perricone, and Chad and Andrew Payton, because they can take that initial discussion and actually see how it can be formulated into a functional and deliverable research project. And we've had several projects where people have just contacted us.  We are very fortunate that we have a very, very strongly supportive Chair, Miss Paula Madison, who actually sometimes gets cold called, “I'm interested in doing this.” And I think there's been some examples, both in the cosmetic space and in the diagnostic space that we've been engaged in, where somebody just made a phone call, not even knowing that we actually have this infrastructure for applied research, and t's worked out quite well.

 

Pat Perdue  31:17

Amazing. And it sounds like the overarching theme of all this is it's a lot easier than people may think, to benefit from this program.

 

Chad Lever  31:28

Don't waste time. Start speaking to us early, because, you might be germinating your business, your idea. We're now onboarding the Skills Program, the Seneca Center for Innovation, Life Sciences, new projects for the Fall /Winter of next year. That's how subscribed we are. And partners should not hesitate to contact us and have an open conversation, we have NDAs we operate on that principle and are open to conversations.

 

Pat Perdue  31:59

That's amazing. Well, in for my last question. One of the things that I've been asking all of the guests on the podcast around COVID-19, and our own personal experience, around COVID-19. I know for me, I've noticed some things about myself, I've been a lot more sedentary than I've been, you know, in the rest and at any other point in my life. And that has prompted some new discoveries about myself. So Frank, I'm going to start with you, has there been anything that you've discovered about yourself or maybe learned or rediscovered as a result of this pandemic experience?

 

Frank Mirante  32:37

I really believe that if there's a need, there could be an innovation. And I think COVID is a great example that if three years ago, somebody said, we're going to develop a vaccine from inception, to putting it into somebody's arm, in the course of a year, I think people would have said, that's absolutely unprecedented. It's ridiculous. It's never going to happen. And here we are in 2021, where, in a year's time, the understanding of this infectious disease has evolved dramatically. Multiple vaccines have been developed, clinical trials have been conducted, Health Canada has approved these vaccines and we're vaccinating our most vulnerable. I think, this pandemic has really illustrated that, as a community, we can achieve great things. And I think the fact that we are vaccinating our frontline workers, and our most vulnerable is a great case in point.

 

Pat Perdue  33:37

Amazing. And do you think it has forever changed the landscape of vaccine development and distribution?

 

Frank Mirante  33:44

I believe so. I think now, I think we illustrated a couple of things. One, we don't have to take 8t to 10 years to develop a product. And also, I think it also illustrates the urgency of having the infrastructure to enable that rapid response. And I think, and I'll be honest with you, I think I think Canada, as a country has been caught with its pants down, we have some of the most talented and capable scientists on the planet. And yet, we're just now realizing that we really should have the infrastructure to be developing our own vaccines for our own security. And I think we're making great strides towards that goal. But I think now suddenly, we have the ability to maybe apply that paradigm to other areas of need.

 

Pat Perdue  34:34

Very interesting observation. And Chad, I'm going to ask the same question of you. How has your experience with COVID-19 or the pandemic in general impacted you either professionally or even personally for some self-discoveries?

 

Chad Lever  34:49

Well, like everyone on both fronts, and you know, as you said in your introduction, I did my training in epidemiology. I was on the Toronto Public Health SARS Response Team two years ago as a support running tables and graphs. And when you asked that question, what came to mind was, my faith in society actually has been propped up. Because look at how, Canadian society has responded in a way that is supportive of one another, for, you know, entirely the most part we are, you know, we're innovating at work. We're protecting our community and our families. And, there's been extended hits from COVID, in my family and my community. I'm from a small town, Bobcaygeon, that had the first long term care hit. Two thirds of the residents were lost in that first wave. So, it does hit close to home, but I have a lot of faith in society and how Canadians have responded for one another. And I think I can echo Frank's comment more, that the wakeup calls for Canada on the innovation front is nigh. And we have the expertise here. And it is time to really advance our innovation sector and bring Canada more onto the global stage in that regard.

 

Pat Perdue  36:12

Well, in leaving us there, I have a whole hour's worth of questions for that very topic! But I'm going to end the conversation here. Frank Mirante, Chad Lever, thank you both for your time and your expertise. I really appreciate your joining the Seneca Proud podcast today. Thank you very much.

 

Chad Lever  Frank 36:33

Thank you, Pat. It's been a pleasure. Thank you.

 

Pat Perdue  36:34

I would like to thank Dr. Frank Mirante, and Chad Lever for their time and expertise in joining the Seneca Proud podcast. What really resonated with me was the level of genuine partnership Seneca Innovation provides and the incredible wealth of talent that Seneca College makes available to participate in and drive this game changing research. I also found it super interesting that these product breakthroughs don't come in a straight line. But they're truly the outcome of creative, iterative thinking from all parties. It's a genuinely creative, innovative partnership. And it's all right here at Seneca College. And thank you for listening and joining me on this journey. Until next time, I'm Pat Perdue. Stay proud Seneca.